GZMB and neoplasm: Detection of the tumour GZMB marker by flow cytometry and immunohistochemistry methods, respectively, showed a significant upregulation of GZMB expression in the MCT4i group (Figure 8D,E), indicating that inhibiting SLC16A3 could effectively enhance the cytotoxic ability of immune cells.